Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,277 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating IMA-026 in Healthy Subjects

NCT00517348
View directory record Official record
Conditions
Healthy
Interventions
IMA-026
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2009 · Synced Oct 28, 2026, 10:28 AM EDT
Recruiting Phase 2 Interventional

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

NCT07637578
View directory record Official record
Conditions
Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
Elranatamab, Tocilizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Denver, Colorado • Columbia, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 28, 2026, 10:28 AM EDT
Recruiting Phase 2 Interventional

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647
View directory record Official record
Conditions
Gram-negative Bacterial Infections
Interventions
ATM-AVI, BAT
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Months to 17 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 28, 2026, 10:28 AM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

NCT07206225
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
PF-08052667, Sasanlimab, BCG, PF-02921367
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
54
States / cities
Birmingham, Alabama • Ruskin, Florida • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01372150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained release, fluoxetine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
41
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 4 Interventional Results available

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

NCT01010204
View directory record Official record
Conditions
Smoking Cessation, Bipolar Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
DuBois, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

NCT01055704
View directory record Official record
Conditions
Gastric Motility Disorder
Interventions
Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 28, 2026, 10:28 AM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

NCT00143247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exubera® (inhaled insulin)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
12
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

NCT00259649
View directory record Official record
Conditions
Migraine
Interventions
eletriptan
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

NCT06717425
View directory record Official record
Conditions
Obesity
Interventions
PF-07976016, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 74 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Anaheim, California • San Diego, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 2 Interventional

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091
View directory record Official record
Conditions
Long COVID
Interventions
Nirmatrelvir, Ritonavir, Placebo
Drug
Lead sponsor
Harlan M Krumholz
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

Exercise to Treat Depression in Individuals With Coronary Heart Disease

NCT00302068
View directory record Official record
Conditions
Depression, Heart Diseases
Interventions
Supervised Aerobic Exercise, Sertraline, Placebo Pill.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 28, 2026, 10:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT05574010
View directory record Official record
Conditions
Celiac Disease
Interventions
Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
Drug · Other
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Not applicable Interventional

Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002040
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 28, 2026, 10:28 AM EDT
Completed No phase listed Observational Results available

Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)

NCT01302080
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
sertraline, psychotherapy
Drug · Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
44
States / cities
Dothan, Alabama • Imperial, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PF-07868489, Placebo for PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
16
States / cities
Anaheim, California • Costa Mesa, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ibuprofen 5% Topical Gel CIPT

NCT01771822
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 5% topical gel, Topical gel vehicle, Sodium lauryl sulfate 0.2%, Sodium chloride solution 0.9% (saline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Carlstadt, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating IMA-638 in Healthy Japanese

NCT00340327
View directory record Official record
Conditions
Healthy
Interventions
IMA-638
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
20 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 2 Interventional

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

NCT00425256
View directory record Official record
Conditions
Sexual Arousal Disorder
Interventions
Bremelanotide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
21 Years to 70 Years · Female only
Timeline
2006 – 2007
U.S. locations
20
States / cities
Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 28, 2026, 10:28 AM EDT
Withdrawn No phase listed Observational

Axitinib Therapy Management Study

NCT04555603
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Inlyta, Bavencio, Keytruda
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 28, 2026, 10:28 AM EDT
Completed No phase listed Observational

An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS

NCT00754273
View directory record Official record
Conditions
Methicillin-resistant Staphylococcal Aureus Pneumonia
Interventions
etest susceptability testing
Other
Lead sponsor
University of Kentucky
Other
Eligibility
Not listed
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 28, 2026, 10:28 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

NCT02528188
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
299
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 28, 2026, 10:28 AM EDT